Showing posts with label Multiple Myeloma Therapeutics. Show all posts
Showing posts with label Multiple Myeloma Therapeutics. Show all posts

Tuesday, 4 April 2017

Asia-Pacific Multiple Myeloma Therapeutics Industry Key Trends, Size, Growth, Shares And Forecast Research Report 2021

Researchmoz added Most up-to-date research on "Multiple Myeloma Therapeutics in Asia-Pacific Markets to 2021 - Growth Driven by Rising Prevalence, Continued Success of Velcade, Revlimid and Emerging Supplementary Treatments" to its huge collection of research reports.

Multiple Myeloma (MM) is a hematological malignancy characterized by the proliferation of plasma cells in the bone marrow. The disease is incurable; although over the past decade there have been significant improvements in therapy, driven by a greater understanding of pathophysiology. MM represents about 0.8–1% of all cancer cases worldwide and approximately 10% of all hematological cancers, with incidence rates ranging from 0.4 to 5 per 100,000 persons in different parts of the world.

Without any treatment, the median survival of a myeloma patient is about six months, but this can be extended with the use of various forms of treatment. There are now five classes of drugs used in the treatment of myeloma: immunomodulatory drugs, chemotherapy, proteasome drugs, Histone Deacetylase (HDAC) inhibitors and steroids. Many of the notable drugs in these classes were approved over the past 10–15 years. Treatment using these novel drugs and high-dose chemotherapy with hematopoietic Stem-Cell Transplant (SCT) has been shown to improve median survival to five years, which makes this the current standard therapy. However, many patients suffer relapse or develop treatment resistance, leaving a need to develop safe and effective treatments that prolong the duration of remission and improve survival.

To Get Sample Copy of Report visit @ http://www.researchmoz.us/enquiry.php?type=S&repid=471697

Scope

The different  segments of patients with MM are based on their eligibility for an SCT

- What combination therapies are used for various segments?
- What are the treatment options available for myeloma, providing an overview of the front-line, second-line and third-line therapies available?

There are seven main marketed products for MM, with most of the novel drugs being approved in the last decade.

- What are the dominant mechanisms of action across marketed products?
- Which products are approved currently in each country and which ones are likely to be launched within the forecast period?
- Which product is used more in each country?
- Will there be any label expansions of existing market leaders in any of the countries?

Epidemiology of MM is significantly different in Asia-Pacific countries from that in the major markets.

- What are the various epidemiology trends in each country?
- What factors contribute to the overall epidemiology?

The MM pipeline consists of more than 250 products in active development. Small molecules are the most abundant molecule type in the pipeline, accounting for 48% of all products.

- What are the various pipeline products based on molecule type, mechanism of action and stage of development?
- Which class is most prominent within the pipeline?
- Do the pipeline molecules offer an advantage over commercially proven mechanisms?
- What are the late-pipeline products expected to be launched in each country in the near future?

Analysis of clinical trials since 2006 identified that MM products have a high rate of attrition.

- How do failure rates vary by product stage of development, molecule type, and mechanism of action?
- How do other factors such as average trial duration and trial size influence the costs and risks associated with product development?
- What are the current promising pipeline drugs and their efficacy data?

Over the 2014–2020 forecast period, the MM market in Australia, China, India and Japan is expected to increase in value at a CAGR of 7.4%, from $1.7 billion to about $2.8 billion.

- Which markets make the most significant contribution to the current market size?
- What are the incidence, diagnosis and treatment trends in these markets?
- What are the factors responsible for difference in the treatment patterns within the four markets?
- Which factors will influence growth rates?
- Will new market entrants lead to substantial changes in annual therapy costs?

Some key marketed products are expected to expire in the forecast period, and promising pipeline molecules are likely to be launched in the near future.

- Will patent expirations or emerging pipeline molecules threaten the commercial success of existing drugs?
- Will the patent expiration be offset by the approval of new therapies?

Reasons to buy

This report will enable you to -

- Understand the clinical context of MM by considering symptoms, etiology, pathophysiology, epidemiology, diagnosis, and treatment options.
- Identify the therapeutic strategies, products, and companies that dominate the current marketed products landscape and recognize gaps and areas of unmet need.
- Appreciate key pipeline trends in molecule type, administration route, mechanism of action, and novelty.
- Consider market opportunities and potential risks by examining trends in clinical trial size, duration, and failure rate by stage of development, molecule type, and mechanism of action.
- Recognize the late-stage pipeline molecules that have demonstrated strong therapeutic potential by examining clinical trial data and multi-scenario product forecast projections.
- Compare treatment usage patterns, annual therapy costs, and market growth projections for India, China, Australia and Japan.
- Discover trends in licensing and co-development deals concerning MM products and identify the major strategic consolidations that have shaped the commercial landscape.

Make an Enquiry of this report @ http://www.researchmoz.us/enquiry.php?type=E&repid=471697

Wednesday, 22 March 2017

Multiple Myeloma Therapeutics in Major Developed Markets Key Trends, Size, Growth, Shares And Forecast Research Report 2021

Researchmoz added Most up-to-date research on "Multiple Myeloma Therapeutics in Major Developed Markets to 2021 - Growth Driven by Rising Prevalence, Continued Success of Revlimid and Emerging Supplementary Treatments" to its huge collection of research reports.

Multiple Myeloma (MM) is a hematological malignancy characterized by the proliferation of plasma cells in the bone marrow. It is the second-most frequently diagnosed hematological malignancy, with an annual prevalence in the US of about 45,000. The disease is considered incurable, although the past decade has seen significant improvements in therapy, driven by a greater understanding of pathophysiology. Many of the leading drugs in the market were approved over the past 10–15 years, and have improved median survival rates by about 50%.

The MM pipeline contains 267 products in active development, encompassing a range of molecule types and therapeutic targets. The innovation that has characterized the market over recent years is also clearly present in the current pipeline, with a strong presence of novel, targeted products.

To Get Sample Copy of Report visit @ http://www.researchmoz.us/enquiry.php?type=S&repid=316442

Scope

- The MM market landscape has undergone significant change over the past two decades.
- Which classes of drug have emerged to dominate the market?
- What survival benefits have these drugs produced?
- How do the leading marketed therapies compare clinically?
- The pipeline contains a range of molecule types and molecular targets not present in the current market, including a strong focus on therapies targeting common oncogenic pathways, such as the Phosphoinositide 3-Kinase/Protein Kinase B (PI3K/Akt) pathway.
- Which molecular targets appear most frequently in the pipeline?
- How will the new therapies be positioned in the treatment of MM?
- How have selected late-stage pipeline therapies performed in clinical trials?
- MM clinical trials have an overall attrition rate of 78%.
- What are the failure rates for individual Phases of clinical development?
- How do MM clinical trial characteristics, including failure rate, duration, and size compare against oncology and industry averages?
- The MM market is forecast to rise from a value of $7.3 billion in 2014 to $8.9 billion in 2021, at a CAGR of 2.9% across the eight major markets assessed.
- How much of a role will disease prevalence and new product approvals play in market growth?
- Will generic competition have a significant impact on the market over the forecast period?
- There have been 39 licensing deals and 22 co-development deals pertaining to MM products since 2006.
- Which territories show the most deal activity?
- What were the trends in deal completion by product stage of development?
- What were the conditions of the key licensing or co-development deals to take place in MM?

Reasons to buy

- Understand the current clinical and commercial landscape through a comprehensive study of disease pathogenesis, diagnosis, prognosis, and the current treatment algorithm used in MM.
- Assess the safety and efficacy of current treatment options, with extensive product profiles on prominent marketed therapies and a heatmap directly comparing safety and efficacy data.
- Analyze the MM pipeline and stratify by stage of development, molecule type, and molecular target. The most promising late-stage therapies are profiled and assessed in terms of clinical performance and competitiveness, alongside a single-product forecast.
- Predict growth in market size in eight major markets, with in-depth market forecasting from 2014–2021. The forecasts will provide an understanding of how epidemiology trends, new drug entry, and patent expirations will influence market value.
- Identify commercial opportunities in the MM deals landscape by analyzing trends in licensing and co-development deals, and by profiling the most significant deals that have occurred in this indication in recent years.

Make an Enquiry of this report @ http://www.researchmoz.us/enquiry.php?type=E&repid=316442

Blood Thawing System Market Insights Shared in Detailed Report

Blood Thawing System Market: Introduction According to the report, the global  blood thawing system market  was valued at ~US$ 174 Mn in 2...